IC | FRC | |||||||
---|---|---|---|---|---|---|---|---|
Treatment | Planned time (min) | na | Mean (SE) IC, L | Mean (SE) difference from placebo, L | p value | Mean (SE) FRC, L | Mean (SE) difference from placebo, L | p value |
Study 1222.37 | ||||||||
Placebo | −30 (pre-dose/trough) | 134-135 | 2.170 (0.040) | 4.977 (0.062) | ||||
Olodaterol 5 μg | 139-140 | 2.289 (0.040) | 0.119 (0.034) | 0.0005 | 4.855 (0.061) | −0.122 (0.069) | 0.0784 | |
Olodaterol 10 μg | 134 | 2.262 (0.040) | 0.092 (0.034) | 0.0073 | 4.862 (0.062) | −0.115 (0.070) | 0.1013 | |
Placebo | 60 (post-dose) | 134-135 | 2.221 (0.040) | 4.950 (0.064) | ||||
Olodaterol 5 μg | 139-140 | 2.427 (0.040) | 0.206 (0.035) | <0.0001 | 4.740 (0.063) | −0.210 (0.066) | 0.0015 | |
Olodaterol 10 μg | 134 | 2.437 (0.040) | 0.216 (0.036) | <0.0001 | 4.577 (0.064) | −0.373 (0.066) | <0.0001 | |
Study 1222.38 | ||||||||
Placebo | −30 (pre-dose/trough) | 147 | 2.463 (0.041) | 4.842 (0.062) | ||||
Olodaterol 5 μg | 145-146 | 2.613 (0.041) | 0.150 (0.040) | 0.0002 | 4.757 (0.063) | −0.086 (0.053) | 0.1048 | |
Olodaterol 10 μg | 141-142 | 2.618 (0.042) | 0.154 (0.040) | 0.0001 | 4.723 (0.063) | −0.120 (0.053) | 0.0246 | |
Placebo | 60 (post-dose) | 147 | 2.493 (0.040) | 4.770 (0.065) | ||||
Olodaterol 5 μg | 145-146 | 2.725 (0.040) | 0.232 (0.036) | <0.0001 | 4.557 (0.065) | −0.213 (0.053) | <0.0001 | |
Olodaterol 10 μg | 141-142 | 2.696 (0.040) | 0.203 (0.036) | <0.0001 | 4.583 (0.065) | −0.187 (0.054) | 0.0005 |